AppClone announced on the 24th that it has developed the antibody therapeutic platform "mRMab" by merging messenger ribonucleic acid (mRNA) technology with existing antibody discovery technology.
According to AppClone, the key to this technology is designing mRNA corresponding to specific disease proteins to induce an immune response in animals. When disease proteins are produced in their original form within the animal's body, the immune system recognizes them and forms specific antibodies.
The existing antibody development method often failed to develop antibodies for intractable diseases because it used artificially synthesized proteins from outside, which had structural differences compared to disease proteins produced in the body. Additionally, preparing artificially synthesized proteins required a lot of time and expense.
In contrast, AppClone explained that the mRMab method allows the natural formation of complex proteins by generating disease proteins in the body. This means that therapeutic antibodies for intractable disease proteins can also be effectively developed.
The market size for monoclonal antibody therapeutics, a representative antibody-based therapeutic, is expected to grow at an average annual rate of 12.5%, from $186.6 billion in 2022 to $609 billion by 2032.
AppClone plans to operate a differentiated new drug platform and provide new drug development and antibody development services to pharmaceutical companies, research institutes, and hospitals both domestically and internationally.
A representative from AppClone said, "Developing therapeutic antibodies using the mRMab platform will bring innovations beyond existing methods," noting that it will play an important role in developing antibody therapeutics for intractable diseases such as cancer and new infectious diseases.